- A new daily Weight Loss pill, amycretin, developed by Novo Nordisk, has shown promising results in initial studies.
- In trials, patients receiving weekly amycretin injections lost an average of 24.3 percent of their body weight over 36 weeks.
- Patients taking daily amycretin tablets achieved an average weight loss of 13.1 percent over 12 weeks.
- Amycretin works by targeting GLP-1 and amylin receptors to help control blood sugar and appetite.
- Side effects, including nausea and vomiting, were reported as mostly mild to moderate and resolved by the end of treatment.
IN FULL
